LFCR
Lifecore Biomedical, Inc.
There isn't enough reported data to score LFCR yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LFCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Stable | |
| Weak |
LFCR's cash flow is currently stable, but its profitability and balance sheet are weak. There isn't enough data to rate its revenue.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LFCR PE Valuation
LFCR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LFCR Forward outlook
There aren't enough analyst estimates for LFCR to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LFCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.16 | +$0.11 |
| Q2 2025 | -$1.27 | -497% |
| Q1 2025 | -$1.39 | -$0.53 |
| Q4 2024 | -$0.50 | +$2.11 |
| Q3 2024 | $0.14 | +$3.56 |
| Q2 2024 | $0.32 | +$3.77 |
| Q1 2024 | -$0.86 | +$3.11 |
| Q4 2023 | -$2.61 | +$0.46 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 490% for LFCR versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
LFCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.3M | -19% |
| Q2 2026 | $34.2M | -6.2% |
| Q1 2026 | $23.2M | -34% |
| Q4 2025 | $44.4M | +36% |
| Q3 2025 | $31.1M | +26% |
| Q2 2025 | $36.4M | -3.8% |
| Q1 2025 | $35.2M | -1.5% |
| Q4 2024 | $32.6M | +8% |
LFCR's revenue has slid since its 2020 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.5% | +6.3 points |
| Q2 2026 | 7.5% | -7.1 points |
| Q1 2026 | -20% | +5.5 points |
| Q3 2025 | -9.9% | +37 points |
| Q2 2025 | 15% | +8.9 points |
| Q1 2025 | -26% | -23 points |
| Q4 2024 | -6% | -1.1 points |
| Q3 2024 | -47% | -12 points |
LFCR's operating margin was −3.5% last quarter, down 18 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LFCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LFCR on profitability, with a higher operating margin.
LFCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6M | +24036% |
| Q2 2026 | -$2.7M | -183% |
| Q1 2026 | $3.6M | +$7.8M |
| Q4 2025 | -$986.3K | +$7.6M |
| Q3 2025 | $25K | +$4.1M |
| Q2 2025 | $3.3M | -62% |
| Q1 2025 | -$4.3M | +$3.5M |
| Q4 2024 | -$8.6M | -$5.6M |
LFCR's free cash flow has turned positive after six years mostly in the red: $6M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
LFCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +271K shares |
| 1 year | +1.2% | +443K shares |
| 3 years | +24% | +7.4M shares |
| 5 years | +29% | +8.4M shares |
| Available history | +30% | +8.7M shares |
LFCR has 38M diluted shares, up 1.2% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LFCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LFCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 5,820.6x | High |
| Q3 2021 | 8.2x | High |
| Q2 2021 | 25.7x | High |
| Q4 2019 | 8.5x | High |
LFCR's net debt is more than 20 years of its operating earnings (EBITDA).
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LFCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 90.1 | Overbought |
LFCR's weekly RSI is 61 (neutral) and its Stochastic is 90 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LFCR PE vs Healthcare Sector
| Metric | LFCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFCR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LFCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.2% above |
| 20 week MA | $5.21 | 23% above |
| 50 week MA | $5.85 | 9.4% above |
| 100 week MA | $6.38 | 0.3% above |
| 200 week MA | $6.45 | 0.8% below |
LFCR has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LFCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $10.1 | -12% |
| 2021 | $10.1 | $11.0 | +8.7% |
| 2022 | $11.0 | $6.93 | -37% |
| 2023 | $6.93 | $6.19 | -11% |
| 2024 | $6.19 | $7.28 | +18% |
| 2025 | $7.28 | $8.30 | +14% |
| 2026 YTD | $8.30 | $6.40 | -23% |
LFCR has finished lower in three of the last six years. It's down 23% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over LFCR on returns for 2026, with the stronger performance.